Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 1/20 | 0.42 |
| ▸ | BTK | Q06187 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 4/20 | 0.41 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.41 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.41 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | ACE | P12821 | 1/20 | 0.38 |
| ▸ | GABRP | O00591 | 1/20 | 0.37 |
| ▸ | GABRD | O14764 | 1/20 | 0.37 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.37 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.37 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.37 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.37 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.37 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.37 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22100987 | 1.00 | ANPEP (0.42) | ANPEPBTKTSHRSLC6A1SLC6A11 | |
| SCHEMBL3939408 | 1.00 | ANPEP (0.42) | ANPEPBTKTSHRSLC6A1SLC6A11 | |
| SCHEMBL2183635 | 1.00 | ANPEP (0.42) | ANPEPBTKTSHRSLC6A1SLC6A11 | |
| SCHEMBL4748647 | 1.00 | ANPEP (0.42) | ANPEPBTKTSHRSLC6A1SLC6A11 | |
| SCHEMBL404285 | 1.00 | ANPEP (0.42) | ANPEPBTKTSHRSLC6A1SLC6A11 | |
| SCHEMBL3670041 | 1.00 | ANPEP (0.42) | ANPEPBTKTSHRSLC6A1SLC6A11 | |
| SCHEMBL5432415 | 1.00 | ANPEP (0.42) | ANPEPBTKTSHRSLC6A1SLC6A11 | |
| SCHEMBL5428215 | 0.98 | ANPEP (0.41) | ANPEPBTKTSHRSLC6A1SLC6A11 | |
| Cesium SCHEMBL5428219 | 0.98 | ANPEP (0.41) | ANPEPBTKTSHRSLC6A1SLC6A11 | |
| SCHEMBL9729349 | 0.95 | TSHR (0.43) | ANPEPBTKTSHRSLC6A1SLC6A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112041304-B | Isoxazole N-linked carbamoyl cyclohexyl acids as LPA antagonists | 百时美施贵宝公司 | 2025-03-07 | — | — | CN | disclosed |
| US-11918582-B2 | Pyrazole pyrimidine compounds and uses thereof | RAPT THERAPEUTICS, INC. (US) | 2024-03-05 | — | — | US | disclosed |
| EP-3704113-B1 | BRIDGED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-10-11 | — | — | EP | disclosed |
| EP-3728216-B1 | PYRAZOLE N-LINKED CARBAMOYL CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2023-09-06 | — | — | EP | disclosed |
| WO-2023109878-A1 | TRIAZASPIRO LPAR1 ANTAGONIST AND USE THEREOF | 武汉人福创新药物研发中心有限公司 | 2023-06-22 | — | — | WO | disclosed |
| EP-3728196-B1 | PYRAZOLE O-LINKED CARBAMOYL CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2023-04-05 | — | — | EP | disclosed |
| EP-3728222-B1 | CYCLOHEXYL ACID PYRAZOLE AZINES AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2023-03-29 | — | — | EP | disclosed |
| EP-3728242-B1 | CYCLOHEXYL ACID ISOXAZOLE AZOLES AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2023-03-01 | — | — | EP | disclosed |
| WO-2022174882-A1 | 5-MEMBERED HETEROCYCLYL CARBAMATE DERIVATIVES AS DUAL LPA RECEPTOR 1 AND LPA RECEPTOR 2 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2022-08-25 | — | — | WO | disclosed |
| US-11384067-B2 | Pyrazole n-linked carbamoyl cyclohexyl acids as LPA antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-07-12 | — | — | US | disclosed |
| US-20100249147-A1 | SULFONYL-SUBSTITUTED 6-MEMBERED RING DERIVATIVE | MSD K.K. (JP) | 2010-09-30 | — | — | US | disclosed |
| US-7709494-B2 | for lowering blood glucose, treating diabetes, or increasing insulin release, hyperglycemia; (1S,3R)-3-(4,5-Diphenylpyrimidin-2-yloxymethyl)cyclohexanecarboxylic acid | SANOFI-AVENTIS (DE) | 2010-05-04 | — | — | US | disclosed |
| US-20090149486-A1 | 4,5-DIPHENYL-PYRIMIDINYL-OXY OR -MERCAPTO SUBSTITUTED CARBOXYLIC ACIDS, METHOD FOR THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2009-06-11 | — | — | US | disclosed |
| EP-1805316-B1 | PROCESS FOR THE PREPARATION OF THE ENANTIOMERIC FORMS OF CIS-3-HYDROXYCYCLOHEXANE CARBOXYLIC ACID DERIVATIVES EMPLOYING HYDROLASES | SANOFI AVENTIS DEUTSCHLAND (DE) | 2009-04-15 | — | — | EP | disclosed |
| WO-2008119715-A1 | 1- (1-CYCLOHEXYL-4-PIPERIDINYL) -1, 3-DIHYDRO-2H-BENZIMIDAZOL-2-ONE DERIVATIVES WHICH HAVE ACTIVITY ON THE M1 RECEPTOR AND THEIR USE IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2008-10-09 | — | — | WO | disclosed |
| US-20070197788-A1 | METHOD FOR THE PREPARATION OF ENANTIOMER FORMS OF CIS-CONFIGURED 3-HYDROXYCYCLOHEXANE CARBOXYLIC ACID DERIVATIVES USING HYDROLASES | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-08-23 | — | — | US | disclosed |
| US-20070197788-A1 | METHOD FOR THE PREPARATION OF ENANTIOMER FORMS OF CIS-CONFIGURED 3-HYDROXYCYCLOHEXANE CARBOXYLIC ACID DERIVATIVES USING HYDROLASES | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-08-23 | — | — | US | disclosed |
| EP-1805316-A2 | METHOD FOR PRODUCING THE ENANTIOMER FORMS OF CIS-CONFIGURED 3-HYDROXYCYCLOHEXANE CARBOXYLIC ACID DERIVATIVES USING HYDROLASES | Sanofi-Aventis Deutschland GmbH (DE) | 2007-07-11 | — | — | EP | disclosed |
| CN-1989253-A | Method for producing enantiomeric forms of 3-hydroxycyclohexanecarboxylic acid derivatives in cis-configuration using a hydrolase | SANOFI AVENTIS DEUTSCHLAND (DE) | 2007-06-27 | — | — | CN | disclosed |
| WO-2006015716-A2 | METHOD FOR PRODUCING THE ENANTIOMER FORMS OF CIS-CONFIGURED 3-HYDROXYCYCLOHEXANE CARBOXYLIC ACID DERIVATIVES USING HYDROLASES | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149486-A1 | 4,5-DIPHENYL-PYRIMIDINYL-OXY OR -MERCAPTO SUBSTITUTED CARBOXYLIC ACIDS, METHOD FOR THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | SLC5A1, SLC5A2, DPP4 | ANPEP 377/4885BTK 2474/4885TSHR 1195/4885 |
| US-20100249147-A1 | SULFONYL-SUBSTITUTED 6-MEMBERED RING DERIVATIVE | CHRM2, CHRM3, CHRM1 | ANPEP 3599/4885BTK 2200/4885TSHR 28/4885 |
| US-11918582-B2 | Pyrazole pyrimidine compounds and uses thereof | DCK, MCL1, DTYMK | ANPEP 3417/4885BTK 783/4885TSHR 4605/4885 |
| US-11384067-B2 | Pyrazole n-linked carbamoyl cyclohexyl acids as LPA antagonists | LPAR3, LPAR4, LPAR5 | ANPEP 2251/4885BTK 1808/4885TSHR 374/4885 |
| US-20070197788-A1 | METHOD FOR THE PREPARATION OF ENANTIOMER FORMS OF CIS-CONFIGURED 3-HYDROXYCYCLOHEXANE CARBOXYLIC ACID DERIVATIVES USING HYDROLASES | CES1, COASY, CYP51A1 | ANPEP 652/4885BTK 4808/4885TSHR 3448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.